![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 10, 2003 6:30:37 PM
As we learned with Retinome, chips are better suited for complex tests but they can also be prohibitively expensive. Usually a company has the option of weighing performance vs. cost when marketing a product. But in this case, I don't think performance can be compromised. So it boils down to cost.
So I'm interested to see how this unfolds - which chip supplier they use, whether they can get it down to a marketable cost and if it will be the first DNAP product to achieve the coup d'etat in genetics testing that many of us have been waiting for.
Something to consider: Ancestry 3.0, whenever it comes out, can be marketed to many geographic regions that 2.0 cannot. Genetic/cultural stratification is a universal condition.
FEATURED Element79 Gold Corp Provides Update on Nevada Portfolio • Aug 23, 2024 8:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM